Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions

British Journal of Clinical Pharmacology

Volumn 83, Issue 5, 2017, Pages 1118-1125

  Bager, Palle ^a   Hvas, Christian L ^a   Dahlerup, Jens F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

anaemia; inflammatory bowel disease; intravenous iron; iron deficiency

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON ISOMALTOSE; PHOSPHATE; DISACCHARIDE; FERRIC ION; IRON ISOMALTOSIDE 1000; MALTOSE;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISACCHARIDES; DRUG HYPERSENSITIVITY; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPOPHOSPHATEMIA; INFUSIONS, INTRAVENOUS; MALE; MALTOSE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85009460183     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13189     Document Type: Article

References (29)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–D1068.
2. Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211–222.
3. EMA-CHMP (2013). Assessment report for: Iron containing intravenous (IV) medicinal products EMA/549569/2013. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500150771&mid=WC0b01ac058009a3dc (last accessed 27 June 2016).
4. Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia 2013; 2013: 169107.
5. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719–2728.
6. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28: 1793–1803.
7. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94: 2332–2337.
8. Sanchez González R, Ternavasio-de la Vega HG, Moralejo Alonso L, Inés Revuelta S, Fuertes Martín A. Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect. Med Clin (Barc) 2015; 145: 108–111.
9. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014; 72: 49–53.
10. Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti BP. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr 2014; 68: 531–533.
11. Subramanian R, Khardori R. Severe hypophosphatemia: pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000; 79: 1–8.
12. Liu PY, Jeng CY. Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure. J Chin Med Assoc 2004; 67: 355–359.
13. O'Connor LR, Wheeler WS, Bethune JE. Effect of hypophosphatemia on myocardial performance in man. N Engl J Med 1977; 297: 901–903.
14. Ognibene A, Ciniglio R, Greifenstein A, Jarjoura D, Cugino A, Blend D, et al. Ventricular tachycardia in acute myocardial infarction: the role of hypophosphatemia. South Med J 1994; 87: 65–69.
15. Crook MA. Refeeding syndrome: problems with definition and management. Nutrition 2014; 30: 1448–1455.
16. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91–104.
17. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 466–469.
18. Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis 2010; 4: 427–430.
19. Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia 2012; 2012: 172104.
20. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015; 2015: 468675.
21. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women − PREFER a randomized, placebo-controlled study. PLoS One 2014; 9: e94217.
22. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis 2016; 9: 53–64.
23. Reinisch W, Altorjay I, Zsigmond F, Primas C, Vogelsang H, Novacek G, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 1226–1233.
24. Szebeni J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172: 5025–5036.
25. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90: 12–23.
26. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 2014; 23: 411–419.
27. Becker S, Dam G, Hvas CL. Refeeding encephalopathy in a patient with severe hypophosphataemia and hyperammonaemia. Eur J Clin Nutr 2015; 69: 279–281.
28. Turnbull J, Lumsden D, Siddiqui A, Lin J, Lim M. Osmotic demyelination syndrome associated with hypophosphataemia: 2 cases and a review of literature. Acta Paediatr 2013; 102: e164–e168.
29. Rampton D, Folkersen J, Fishbane S, Hedenius M, Howaldt S, Locatelli F, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99: 1671–1676.